首页> 外文期刊>ACS nano >Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer
【24h】

Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer

机译:连续靶向智能纳米探针用于转移性乳腺癌细胞质microRNA的分子识别

获取原文
获取原文并翻译 | 示例
           

摘要

We report smart nanoprobe, hyaluronic acid (HA)-based nanocontainers containing miR-34a beacons (bHNCs), for the intracellular recognition of miR-34a levels in metastatic breast cancer cells, which is distinct from the imaging of biomarkers such of cell membrane receptors such as HER2. In this study, we demonstrate that a nanoscale vesicle that couples a targeting endocytic route, CD44, and a molecular imaging probe enables the efficient detection of specific miRNAs. Furthermore, bHNCs showed no cytotoxicity and high stability due to the anchored HA molecules on the surface of nanocontainers, and enables the targeted delivery of beacons via CD44 receptor-mediated endocytosis. In vitro and in vivo optical imaging using bHNCs also allow the measurement of miR-34a expression levels due to the selective recognition of the beacons released from the internalized bHNCs. We believe that the technique described herein can be further developed as a cancer diagnostic as well as a miRNA-based therapy of metastatic cancer.
机译:我们报告了包含miR-34a信标(bHNCs)的智能纳米探针,基于透明质酸(HA)的纳米容器,用于转移性乳腺癌细胞中miR-34a水平的细胞内识别,这与诸如细胞膜受体等生物标志物的成像截然不同例如HER2。在这项研究中,我们证明,偶联靶向内吞途径CD44和分子成像探针的纳米级囊泡能够有效检测特定的miRNA。此外,由于在纳米容器表面上锚定的HA分子,bHNCs没有显示出细胞毒性和高稳定性,并且能够通过CD44受体介导的内吞作用定向信标。由于对内在化的bHNCs释放出的信标的选择性识别,使用bHNCs进行的体外和体内光学成像也可以测量miR-34a表达水平。我们相信本文所述的技术可以进一步发展为癌症诊断以及基于miRNA的转移性癌症治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号